Page 211 - 2019_05-HaematologicaMondo-web

HLA discrepancy and outcome of second HSCT
Table 1. Patients’ and donor characteristics.
HLA mismatch for graft-versus-host
P
0.138 42
(18-69) (16-73)
P
0.240
0.326
0.852
0.556
0.406
0.001
0.004
0.088
<0.001
0.025
0.029
Match 1 allele ≥2 allele (N=85) mismatch mismatch
(N=160) (N=401) N(%)N(%)N(%)
43 42 42 (18-73) (16-69) (16-70)
0 0.0 24 15.0 276 67.3 0 0.0 35 21.9 350 85.4 0 0.0 101 63.1 340 82.9
47 55.3 96 60.0 229 55.9 38 44.7 64 40.0 172 42.0
45 52.9 79 49.4 168 41.0 23 27.1 30 18.8 78 19.0 15 17.6 37 23.1 106 25.9 2 2.4 14 8.8 49 12.0
45 52.9 89 55.6 254 62.0 15 17.6 30 18.8 81 19.8 6 7.1 4 2.5 9 2.2 6 7.1 15 9.4 20 4.9 10 11.8 11 6.9 22 5.4 3 3.5 11 6.9 15 3.7
HLA mismatch for graft-versus-first donor
≥2 allele mismatch (N=474)
1 allele
mismattch
(N=100)
N (%)N(%) N (%)
Match (N=72)
Recipient age, years Median
(range)
HLA mismatch
Aallele Ballele DR allele
Recipient gender (%) Male
Female
Donor/recipient gender
Match
Male to Female Female to Male Unknown
Diagnosis
Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Malignant lymphoma
Others
Disease risk at transplant
Standard risk 31
High risk 54
Stem cell source
Bone marrow 37 Peripheral blood 18 Cord blood 17
Conditioning regimen
Myeloablative 37
Reduced intensity 48
GvHD prophylaxis
Cyclosporine based 22 Tacrolimus based 63 Others 0
In vivo T-cell depletion
Yes 9 No 76
Year of transplant
1994-2010 30 2011-2016 55
Interval between first and second SCT
44 42 (16-71)
36.5 51 31.9 110 26.8
63.5 109 68.1 291 71.0
43.5 52 32.5 78 19.0 21.2 14 8.8 149 36.3 20.0 34 21.3 247 60.2
43.5 54 33.8 111 27.1
56.5 106 66.3 290 70.7
25.9 27 16.9 74 18.0 74.1 131 81.9 322 78.5 0.0 2 1.3 5 1.2
10.6 29 18.1 104 25.4
89.4 131 81.9 297 72.4
35.3 55 34.4 118 28.8 64.7 105 65.6 283 69.0
0.740
0.183
0.049
0.200
<0.001
0.012
0.228
0.003
0.372
0.008
0.793
0 0.0 23 23.0 0 0.0 26 26.0 0 0.0 51 51.0
47 65.3 59 59 25 34.7 41 41
32 44.4 49 49.0 17 23.6 19 19.0 20 27.8 21 21.0 3 4.2 11 11.0
38 52.8 56 56.0 12 16.7 20 20.0 4 5.6 4 4.0 6 8.3 8 8.0 6 8.3 7 7.0 6 8.3 5 5.0
24 33.3 34 34.0
48 66.7 66 66.0
66 91.7 85 85.0 13 18.1 26 26.0 6 8.3 49 49.0
339 71.5 429 90.5 427 90.1
266 56.1 208 43.9
211 44.5 95 20.0 117 24.7 51 10.8
294 62.0 94 19.8 11 2.3 27 5.7 30 6.3 18 3.8
134 28.3
340 71.7
16 3.4 142 30.0 243 51.3
<12 months ≥12-23 months ≥24 months Missing
29 34.1 71 44.4 206 50.2 23 27.1 45 28.1 106 25.9 27 31.8 37 23.1 67 16.3 6 7.1 7 4.4 22 5.4
26 36.1 44
46 63.9 56
17 23.6 25 52 72.2 74 3 4.2 1
6 8.3 13
66 91.7 87
27 37.5 41 45 62.5 59
23 31.9 38 19 26.4 28 18 25.0 27 12 16.7 7
29 40.3 35 23 31.9 42 10 13.9 7 10 13.9 16
44.0 132 27.8
56.0 342 72.2
25.0 81 17.1 74.0 390 82.3 1.0 3 0.6
13.0 123 25.9
87.0 351 74.1
41.0 135 28.5 59.0 339 71.5
38.0 245 51.7 28.0 127 26.8 27.0 86 18.1 7.0 16 3.4
35.0 212 44.7 42.0 166 35.0 7.0 41 8.6 16.0 55 11.6
Interval between first SCT and first relapse
<12 months
≥2-12 months
≥12 months
Missing 11 12.9 18 11.3 52 12.7
0.217
34 40.0 67 41.9 175 42.7 32 37.6 57 35.6 145 35.4 8 9.4 18 11.3 32 7.8
N: number; GvHD: graft-versus-host disease; SCT: stem cell transplantation.
haematologica | 2019; 104(5)
1057